Ubix Therapeutics Inc. has disclosed proteolysis targeting chimeras (PROTACs) comprising von Hippel-Lindau disease tumor suppressor ligands coupled to a tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) targeting moiety via linker acting as SHP-2 degradation inducers and reported to be useful for the treatment of cancer.